{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:13:44Z","timestamp":1786997624378,"version":"build-2736575974"},"reference-count":153,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","trasci.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion and Apheresis Science"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.transci.2016.04.012","type":"journal-article","created":{"date-parts":[[2016,5,7]],"date-time":"2016-05-07T15:56:11Z","timestamp":1462636571000},"page":"220-231","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["The alternative pathway of complement and the thrombotic microangiopathies"],"prefix":"10.1016","volume":"54","author":[{"given":"Chia Wei","family":"Teoh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Riedl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Licht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.transci.2016.04.012_bib0010","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1055\/s-0034-1376153","article-title":"Spectrum of complement-mediated thrombotic microangiopathies: pathogenetic insights identifying novel treatment approaches","volume":"40","author":"Riedl","year":"2014","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.transci.2016.04.012_bib0015","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1056\/NEJMra1312353","article-title":"Syndromes of thrombotic microangiopathy","volume":"371","author":"George","year":"2014","journal-title":"NEJM"},{"key":"10.1016\/j.transci.2016.04.012_bib0020","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.ejim.2013.05.009","article-title":"Complement activation in diseases presenting with thrombotic microangiopathy","volume":"24","author":"Meri","year":"2013","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.transci.2016.04.012_bib0025","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.amjmed.2012.09.006","article-title":"Untying the knot of thrombotic thrombocytopenic purpura and atypical hemolytic uremic syndrome","volume":"126","author":"Tsai","year":"2013","journal-title":"Am J Med"},{"key":"10.1016\/j.transci.2016.04.012_bib0030","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.it.2007.02.006","article-title":"Complement and coagulation: strangers or partners in crime","volume":"28","author":"Markiewski","year":"2007","journal-title":"Trends Immunol"},{"key":"10.1016\/j.transci.2016.04.012_bib0035","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/0002-9343(52)90022-3","article-title":"An acute febrile pleiochromic anemia with hyaline thrombosis of the terminal arterioles and capillaries: an undescribed disease","volume":"13","author":"Moschcowitz","year":"1952","journal-title":"Am J Med"},{"key":"10.1016\/j.transci.2016.04.012_bib0040","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1055\/s-0034-1376883","article-title":"Inherited and acquired thrombotic thrombocytopenic purpura (TTP) in adults","volume":"40","author":"Kn\u00f6bl","year":"2014","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.transci.2016.04.012_bib0045","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1055\/s-0034-1376152","article-title":"Inherited thrombotic thrombocytopenic purpura in children","volume":"40","author":"Hassenpflug","year":"2014","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.transci.2016.04.012_bib0050","first-page":"905","article-title":"Hemolytic-uremic syndrome: bilateral necrosis of the renal cortex in acute acquired hemolytic anemia","volume":"85","author":"Gasser","year":"1955","journal-title":"Schweiz Med Wochenschr"},{"key":"10.1016\/j.transci.2016.04.012_bib0055","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1055\/s-0034-1375295","article-title":"Treatment of enterohemorrhagic Escherichia coli-induced hemolytic uremic syndrome (eHUS)","volume":"40","author":"W\u00fcrzner","year":"2014","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.transci.2016.04.012_bib0060","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s00431-009-1039-4","article-title":"Clinical practice. Today's understanding of the haemolytic uraemic syndrome","volume":"169","author":"Scheiring","year":"2010","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.transci.2016.04.012_bib0065","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1056\/NEJM200104053441406","article-title":"Complement (part 1)","volume":"344","author":"Walport","year":"2001","journal-title":"NEJM"},{"key":"10.1016\/j.transci.2016.04.012_bib0070","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1056\/NEJM200104123441506","article-title":"Complement (part 2)","volume":"344","author":"Walport","year":"2001","journal-title":"NEJM"},{"key":"10.1016\/j.transci.2016.04.012_bib0075","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.molimm.2004.02.005","article-title":"The human complement factor H: functional roles, genetic variations and disease associations","volume":"41","author":"Rodr\u00edguez de C\u00f3rdoba","year":"2004","journal-title":"Mol Immunol"},{"key":"10.1016\/j.transci.2016.04.012_bib0080","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1365-2249.2007.03553.x","article-title":"Translational mini-review series on complement factor H: structural and functional correlations for factor H","volume":"151","author":"Schmidt","year":"2008","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.transci.2016.04.012_bib0085","doi-asserted-by":"crossref","first-page":"3949","DOI":"10.1021\/bi4003452","article-title":"Functional anatomy of complement factor H","volume":"52","author":"Makou","year":"2013","journal-title":"Biochemistry"},{"key":"10.1016\/j.transci.2016.04.012_bib0090","doi-asserted-by":"crossref","first-page":"8214","DOI":"10.1074\/jbc.M115.693119","article-title":"Insights into the effects of complement Factor H on the assembly and decay of the alternative pathway C3 proconvertase and C3 convertase","volume":"291","author":"Bettoni","year":"2016","journal-title":"J Biol Chem"},{"key":"10.1016\/j.transci.2016.04.012_bib0095","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.clim.2005.10.014","article-title":"Membrane complement regulatory proteins","volume":"118","author":"Kim","year":"2006","journal-title":"Clin Immunol"},{"key":"10.1016\/j.transci.2016.04.012_bib0100","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/BF01837366","article-title":"Membrane proteins that protect against complement lysis","volume":"15","author":"Morgan","year":"1994","journal-title":"Springer Semin Immunopathol"},{"key":"10.1016\/j.transci.2016.04.012_bib0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2015.00262","article-title":"Complement system part I \u2013 molecular mechanisms of activation and regulation","volume":"6","author":"Merle","year":"2015","journal-title":"Front Immunol"},{"key":"10.1016\/j.transci.2016.04.012_bib0110","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1016\/j.molimm.2009.05.271","article-title":"Complement activation by endothelial cells treated with inflammatory cytokines or heme, in the context of atypical hemolytic uremic syndrome","volume":"46","author":"Frimat","year":"2009","journal-title":"Mol Immunol"},{"key":"10.1016\/j.transci.2016.04.012_bib0115","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1182\/blood-2010-05-283564","article-title":"Complement alternative pathway acts as a positive feedback amplification of neutrophil activation","volume":"117","author":"Camous","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.transci.2016.04.012_bib0120","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/1750-1172-6-60","article-title":"Atypical hemolytic uremic syndrome","volume":"6","author":"Loirat","year":"2011","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.transci.2016.04.012_bib0125","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJMra0902814","article-title":"Atypical hemolytic-uremic syndrome","volume":"361","author":"Noris","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.transci.2016.04.012_bib0130","doi-asserted-by":"crossref","first-page":"554","DOI":"10.2215\/CJN.04760512","article-title":"Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults","volume":"8","author":"Fremeaux-Bacchi","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.transci.2016.04.012_bib0135","doi-asserted-by":"crossref","first-page":"E1445","DOI":"10.1002\/humu.21256","article-title":"Mutations in alternative pathway complement proteins in American patients with atypical hemolytic uremic syndrome","volume":"31","author":"Maga","year":"2010","journal-title":"Hum Mutat"},{"key":"10.1016\/j.transci.2016.04.012_bib0140","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1681\/ASN.2012090884","article-title":"Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype","volume":"24","author":"Bresin","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.transci.2016.04.012_bib0145","doi-asserted-by":"crossref","first-page":"407","DOI":"10.2215\/CJN.01260212","article-title":"Complement factor H-related protein 1 deficiency and factor H antibodies in pediatric patients with atypical hemolytic uremic syndrome","volume":"8","author":"Hofer","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.transci.2016.04.012_bib0150","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1182\/blood-2009-05-221549","article-title":"Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome","volume":"115","author":"Moore","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.transci.2016.04.012_bib0155","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1038\/ki.2013.373","article-title":"Prompt plasma exchanges and immunosuppressive treatment improves the outcomes of anti-factor H autoantibody-associated hemolytic uremic syndrome in children","volume":"85","author":"Sinha","year":"2014","journal-title":"Kidney Int"},{"key":"10.1016\/j.transci.2016.04.012_bib0160","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/ajt.12077","article-title":"Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome","volume":"13","author":"Le Quintrec","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transci.2016.04.012_bib0165","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1111\/j.1600-6143.2008.02297.x","article-title":"Complement mutation-associated de novo thrombotic microangiopathy following kidney transplantation","volume":"8","author":"Le Quintrec","year":"2008","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transci.2016.04.012_bib0170","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1111\/j.1600-6143.2012.04124.x","article-title":"Antibody mediated rejection associated with complement factor H-related protein 3\/1 deficiency successfully treated with eculizumab","volume":"12","author":"Noone","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transci.2016.04.012_bib0175","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1182\/blood-2013-05-501445","article-title":"Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy","volume":"122","author":"Jodele","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.transci.2016.04.012_bib0180","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.bbmt.2013.12.565","article-title":"Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy","volume":"20","author":"Jodele","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.transci.2016.04.012_bib0185","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1182\/blood-2015-08-663435","article-title":"The genetic fingerprint of susceptibility for transplant-associated thrombotic microangiopathy","volume":"127","author":"Jodele","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.transci.2016.04.012_bib0190","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/ng.2590","article-title":"Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome","volume":"45","author":"Lemaire","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.transci.2016.04.012_bib0195","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1681\/ASN.2009070706","article-title":"Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations","volume":"21","author":"Fakhouri","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.transci.2016.04.012_bib0200","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1007\/s00467-010-1609-8","article-title":"CD46-associated atypical hemolytic uremic syndrome with uncommon course caused by cblC deficiency","volume":"25","author":"Bouts","year":"2010","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.transci.2016.04.012_bib0205","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/S0022-3476(05)81967-5","article-title":"Cobalamin C defect associated with hemolytic-uremic syndrome","volume":"120","author":"Geraghty","year":"1992","journal-title":"J Pediatr"},{"key":"10.1016\/j.transci.2016.04.012_bib0210","first-page":"1374","article-title":"Combined renal thrombotic microangiopathy and pulmonary arterial hypertension is caused by cobalamine C deficiency","volume":"28","author":"Komhoff","year":"2013","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.transci.2016.04.012_bib0215","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1177\/0009922811412942","article-title":"Atypical hemolytic-uremic syndrome in a child presenting with malignant hypertension","volume":"52","author":"Totina","year":"2013","journal-title":"Clin Pediatr (Phila)"},{"key":"10.1016\/j.transci.2016.04.012_bib0220","doi-asserted-by":"crossref","first-page":"4012","DOI":"10.1182\/blood-2013-03-487694","article-title":"Complement factor H mutations are present in ADAMTS13-deficient, ticlopidine-associated thrombotic microangiopathies","volume":"121","author":"Chapin","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.transci.2016.04.012_bib0225","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1093\/ckj\/sft065","article-title":"Cisplatin-induced haemolytic uraemic syndrome associated with a novel intronic mutation of CD46 treated with eculizumab","volume":"6","author":"Gilbert","year":"2013","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.transci.2016.04.012_bib0230","doi-asserted-by":"crossref","first-page":"R12","DOI":"10.1186\/ar4142","article-title":"The spectrum of renal thrombotic microangiopathy in lupus nephritis","volume":"15","author":"Song","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.transci.2016.04.012_bib0235","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1093\/rheumatology\/keq311","article-title":"Thrombotic microangiopathy in systemic lupus erythematosus: a cohort study in North Taiwan","volume":"50","author":"Chen","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.transci.2016.04.012_bib0240","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1681\/ASN.2010111130","article-title":"A clinicopathologic study of thrombotic microangiopathy in IgA nephropathy","volume":"23","author":"El Karoui","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.transci.2016.04.012_bib0245","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.1016\/j.molimm.2009.05.018","article-title":"Autoimmune forms of thrombotic microangiopathy and membranoproliferative glomerulonephritis: indications for a disease spectrum and common pathogenic principles","volume":"46","author":"Skerka","year":"2009","journal-title":"Mol Immunol"},{"key":"10.1016\/j.transci.2016.04.012_bib0250","doi-asserted-by":"crossref","first-page":"46","DOI":"10.2215\/CJN.04700513","article-title":"C3 glomerulopathy: clinicopathologic features and predictors of outcome","volume":"9","author":"Medjeral-Thomas","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.transci.2016.04.012_bib0255","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1093\/ndt\/gfu317","article-title":"Update on C3 glomerulopathy","volume":"31","author":"Barbour","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.transci.2016.04.012_bib0260","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1038\/ki.2013.377","article-title":"C3 glomerulopathy: consensus report","volume":"84","author":"Pickering","year":"2013","journal-title":"Kidney Int"},{"key":"10.1016\/j.transci.2016.04.012_bib0265","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/BF01959094","article-title":"Recurrent haemolytic uraemic syndrome in a boy with focal and segmental glomerulosclerosis","volume":"151","author":"Bokenkamp","year":"1992","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.transci.2016.04.012_bib0270","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1007\/s00467-007-0563-6","article-title":"Thrombotic microangiopathy as a complication in a patient with focal segmental glomerulosclerosis","volume":"22","author":"Benz","year":"2007","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.transci.2016.04.012_bib0275","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.2215\/CJN.02210310","article-title":"Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype","volume":"5","author":"Noris","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.transci.2016.04.012_bib0280","doi-asserted-by":"crossref","first-page":"i1","DOI":"10.1093\/ndt\/gft132","article-title":"Outcome of renal ANCA associated vasculitis (AAV) with complement hyperactivation signs: a retrospective study","volume":"28","author":"Manenti","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.transci.2016.04.012_bib0285","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.2215\/CJN.00120115","article-title":"Association of serum C3 concentration and histologic signs of thrombotic microangiopathy with outcomes among patients with ANCA-associated renal vasculitis","volume":"10","author":"Manenti","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.transci.2016.04.012_bib0290","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1055\/s-0034-1375296","article-title":"Genetics of atypical hemolytic uremic syndrome (aHUS)","volume":"40","author":"Rodr\u00edguez de C\u00f3rdoba","year":"2014","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.transci.2016.04.012_bib0295","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1111\/j.1600-6143.2010.03156.x","article-title":"Thrombotic microangiopathy after kidney transplantation","volume":"10","author":"Noris","year":"2010","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transci.2016.04.012_bib0300","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nri3225","article-title":"The role of complement in the early immune response to transplantation","volume":"12","author":"Sacks","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.transci.2016.04.012_bib0305","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s00467-008-0964-1","article-title":"Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome","volume":"24","author":"Ariceta","year":"2009","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.transci.2016.04.012_bib0310","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00467-015-3076-8","article-title":"An international consensus approach to the management of atypical hemolytic uremic syndrome in children","volume":"31","author":"Loirat","year":"2016","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.transci.2016.04.012_bib0315","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1053\/j.ajkd.2015.03.040","article-title":"Glomerular diseases dependent on complement activation, including atypical hemolytic uremic syndrome, membranoproliferative glomerulonephritis, and C3 glomerulopathy: core curriculum 2015","volume":"66","author":"Noris","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.transci.2016.04.012_bib0320","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/nbt1344","article-title":"Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria","volume":"25","author":"Rother","year":"2007","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.transci.2016.04.012_bib0325","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.transci.2016.04.012_bib0330","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/ki.2014.423","article-title":"Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies","volume":"87","author":"Licht","year":"2015","journal-title":"Kidney Int"},{"key":"10.1016\/j.transci.2016.04.012_bib0335","first-page":"ii11","article-title":"Efficacy and safety of eculizumab treatment for atypical haemolytic uremic syndrome (aHUS) in paediatric patients: subgroup analysis of a retrospective study","volume":"27","author":"Simonetti","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.transci.2016.04.012_bib0340","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.kint.2015.11.026","article-title":"Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome","volume":"89","author":"Greenbaum","year":"2016","journal-title":"Kidney Int"},{"key":"10.1016\/j.transci.2016.04.012_bib0345","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/nrneph.2012.214","article-title":"Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies","volume":"8","author":"Zuber","year":"2012","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.transci.2016.04.012_bib0350","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1056\/NEJMc1001060","article-title":"Prophylactic eculizumab after renal transplantation in atypical hemolytic-uremic syndrome","volume":"362","author":"Zimmerhackl","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.transci.2016.04.012_bib0355","doi-asserted-by":"crossref","first-page":"3337","DOI":"10.1111\/j.1600-6143.2012.04252.x","article-title":"Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation","volume":"12","author":"Zuber","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transci.2016.04.012_bib0360","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/ajt.12032","article-title":"Meningococcal sepsis complicating eculizumab treatment despite prior vaccination","volume":"13","author":"Struijk","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transci.2016.04.012_bib0365","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1007\/s00467-011-1929-3","article-title":"Insufficient protection by Neisseria meningitidis vaccination alone during eculizumab therapy","volume":"26","author":"Bouts","year":"2011","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.transci.2016.04.012_bib0370","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1111\/bjh.12707","article-title":"Complement and cytokine response in acute Thrombotic Thrombocytopenic Purpura","volume":"164","author":"Westwood","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.transci.2016.04.012_bib0375","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1111\/jth.12369","article-title":"Complement activation and mortality during an acute episode of thrombotic thrombocytopenic purpura","volume":"11","author":"Wu","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.transci.2016.04.012_bib0380","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/j.1538-7836.2012.04674.x","article-title":"Complement activation in thrombotic thrombocytopenic purpura","volume":"10","author":"R\u00e9ti","year":"2012","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.transci.2016.04.012_bib0385","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1111\/j.1365-2141.2012.09084.x","article-title":"Eculizumab in the treatment of refractory idiopathic thrombotic thrombocytopenic purpura","volume":"157","author":"Chapin","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.transci.2016.04.012_bib0390","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1056\/NEJMoa0810739","article-title":"Thrombomodulin mutations in atypical hemolytic-uremic syndrome","volume":"361","author":"Delvaeye","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.transci.2016.04.012_bib0395","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1681\/ASN.2013050453","article-title":"Comprehensive genetic analysis of complement and coagulation genes in atypical hemolytic uremic syndrome","volume":"25","author":"Bu","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.transci.2016.04.012_bib0400","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1182\/blood-2013-03-492421","article-title":"Partial ADAMTS13 deficiency in atypical hemolytic uremic syndrome","volume":"122","author":"Feng","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.transci.2016.04.012_bib0405","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.2215\/CJN.02730409","article-title":"Alternative pathway of complement in children with diarrhea-associated hemolytic uremic syndrome","volume":"4","author":"Thurman","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.transci.2016.04.012_bib0410","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1056\/NEJMc1100859","article-title":"Eculizumab in severe Shiga-toxin-associated HUS","volume":"364","author":"Lapeyraque","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.transci.2016.04.012_bib0415","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/S0140-6736(11)61253-1","article-title":"Treatment of severe neurological deficits with IgG depletion through immunoadsorption in patients with Escherichia coli O104:H4-associated haemolytic uraemic syndrome: a prospective trial","volume":"378","author":"Greinacher","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.transci.2016.04.012_bib0420","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1093\/ndt\/gfs394","article-title":"Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E.\u2009coli O104:H4 induced haemolytic-uraemic syndrome: an analysis of the German STEC-HUS registry","volume":"27","author":"Kielstein","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.transci.2016.04.012_bib0425","doi-asserted-by":"crossref","first-page":"e4565","DOI":"10.1136\/bmj.e4565","article-title":"Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study","volume":"345","author":"Menne","year":"2012","journal-title":"BMJ"},{"key":"10.1016\/j.transci.2016.04.012_bib0430","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0055278","article-title":"Symptoms and clinical course of EHEC O104 infection in hospitalized patients: a prospective single center study","volume":"8","author":"Ullrich","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.transci.2016.04.012_bib0435","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1093\/ndt\/gft470","article-title":"Outbreak of Escherichia coli O104:H4 haemolytic uraemic syndrome in France: outcome with eculizumab","volume":"29","author":"Delmas","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.transci.2016.04.012_bib0440","first-page":"1373","article-title":"Eculizumab in Shiga toxin associated hemolytic uremic syndrome: a single center matched-cohort study","volume":"28","author":"Harambat","year":"2013","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.transci.2016.04.012_bib0445","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/dmcn.12161","article-title":"Brain magnetic resonance imaging pattern and outcome in children with haemolytic-uraemic syndrome and neurological impairment treated with eculizumab","volume":"55","author":"Gitiaux","year":"2013","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.transci.2016.04.012_bib0450","doi-asserted-by":"crossref","first-page":"B37","DOI":"10.1053\/j.ajkd.2013.02.091","article-title":"Renal recovery in a child with D+ HUS. Is eculizumab a typical drug?","volume":"61","author":"Dhawan","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.transci.2016.04.012_bib0455","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.mehy.2013.05.030","article-title":"Does dysregulated complement activation contribute to haemolytic uraemic syndrome secondary to Streptococcus pneumoniae","volume":"81","author":"Gilbert","year":"2013","journal-title":"Med Hypotheses"},{"key":"10.1016\/j.transci.2016.04.012_bib0460","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1093\/ndt\/gft198","article-title":"The role of complement in Streptococcus pneumoniae-associated haemolytic uraemic syndrome","volume":"28","author":"Szil\u00e1gyi","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.transci.2016.04.012_bib0465","doi-asserted-by":"crossref","first-page":"753","DOI":"10.3109\/0886022X.2010.486491","article-title":"Triggering of atypical hemolytic uremic syndrome by influenza A (H1N1)","volume":"32","author":"Bento","year":"2010","journal-title":"Ren Fail"},{"key":"10.1016\/j.transci.2016.04.012_bib0470","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1007\/s00467-001-0798-6","article-title":"Hemolytic uremic syndrome due to an altered factor H triggered by neonatal pertussis","volume":"17","author":"Berner","year":"2002","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.transci.2016.04.012_bib0475","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1097\/INF.0b013e31826153fb","article-title":"Atypical hemolytic uremic syndrome associated with Bordetella pertussis infection","volume":"31","author":"Obando","year":"2012","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.transci.2016.04.012_bib0480","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1093\/ndt\/gfp166","article-title":"Varicella as a trigger of atypical haemolytic uraemic syndrome associated with complement dysfunction: two cases","volume":"24","author":"Kwon","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.transci.2016.04.012_bib0485","first-page":"153","article-title":"Eculizumab for salvage in post-transplant thrombotic microangiopathy","volume":"24","author":"Barnett","year":"2011","journal-title":"Transpl Int"},{"key":"10.1016\/j.transci.2016.04.012_bib0490","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1097\/TP.0b013e318230c0bd","article-title":"Successful treatment of de novo posttransplant thrombotic microangiopathy with eculizumab","volume":"92","author":"Wilson","year":"2011","journal-title":"Transplantation"},{"key":"10.1016\/j.transci.2016.04.012_bib0495","doi-asserted-by":"crossref","first-page":"125","DOI":"10.5414\/CN108163","article-title":"Eculizumab for drug-induced de novo posttransplantation thrombotic microangiopathy: a case report","volume":"83","author":"Safa","year":"2015","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.transci.2016.04.012_bib0500","doi-asserted-by":"crossref","first-page":"e58","DOI":"10.1097\/TP.0b013e3182a7fccd","article-title":"Successful treatment of acute thrombotic microangiopathy by eculizumab after combined lung and kidney transplantation","volume":"96","author":"Commereuc","year":"2013","journal-title":"Transplantation"},{"key":"10.1016\/j.transci.2016.04.012_bib0505","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1111\/j.1600-6143.2011.03757.x","article-title":"Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients","volume":"11","author":"Stegall","year":"2011","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transci.2016.04.012_bib0510","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1016\/j.transproceed.2012.09.038","article-title":"Eculizumab treatment of acute antibody-mediated rejection in renal transplantation: case reports","volume":"44","author":"Gonz\u00e1lez-Roncero","year":"2012","journal-title":"Transplant Proc"},{"key":"10.1016\/j.transci.2016.04.012_bib0515","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1016\/j.transproceed.2015.06.029","article-title":"Eculizumab for treatment of refractory antibody-mediated rejection in kidney transplant patients: a single-center experience","volume":"47","author":"Yelken","year":"2015","journal-title":"Transplant Proc"},{"key":"10.1016\/j.transci.2016.04.012_bib0520","doi-asserted-by":"crossref","first-page":"e551","DOI":"10.1542\/peds.2014-2275","article-title":"Eculizumab to treat antibody-mediated rejection in a 7-year-old kidney transplant recipient","volume":"135","author":"Chehade","year":"2015","journal-title":"Pediatrics"},{"key":"10.1016\/j.transci.2016.04.012_bib0525","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1111\/ajt.13183","article-title":"Eculizumab salvage therapy for antibody-mediated rejection in a desensitization-resistant intestinal re-transplant patient","volume":"15","author":"Fan","year":"2015","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transci.2016.04.012_bib0530","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.bbmt.2005.07.012","article-title":"Hemolytic uremic syndrome after bone marrow transplantation: clinical characteristics and outcome in children","volume":"11","author":"Hale","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.transci.2016.04.012_bib0535","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.bbmt.2015.10.002","article-title":"Variable eculizumab clearance requires pharmacodynamic monitoring to optimize therapy for thrombotic microangiopathy after hematopoietic stem cell transplantation","volume":"22","author":"Jodele","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.transci.2016.04.012_bib0540","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/bjh.12202","article-title":"Successful use of eculizumab in a patient with post-transplant thrombotic microangiopathy","volume":"161","author":"Peffault de Latour","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.transci.2016.04.012_bib0545","doi-asserted-by":"crossref","first-page":"3811","DOI":"10.1093\/ndt\/gfr436","article-title":"Three kidneys, two diseases, one antibody","volume":"26","author":"Lorcy","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.transci.2016.04.012_bib0550","doi-asserted-by":"crossref","first-page":"3399","DOI":"10.1093\/ndt\/gfr422","article-title":"Thrombotic microangiopathy mimicking membranoproliferative glomerulonephritis","volume":"26","author":"Brackman","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.transci.2016.04.012_bib0555","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1007\/s00467-015-3166-7","article-title":"Novel factor H mutation associated with familial membranoproliferative glomerulonephritis type I","volume":"30","author":"Alfandary","year":"2015","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.transci.2016.04.012_bib0560","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s00467-015-3306-0","article-title":"Discontinuation of dialysis with eculizumab therapy in a pediatric patient with dense deposit disease","volume":"31","author":"Tran","year":"2016","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.transci.2016.04.012_bib0565","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1007\/s00467-014-2839-y","article-title":"Eculizumab in dense-deposit disease after renal transplantation","volume":"29","author":"S\u00e1nchez-Moreno","year":"2014","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.transci.2016.04.012_bib0570","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s40620-013-0008-1","article-title":"A novel CFHR5 mutation associated with C3 glomerulonephritis in a Turkish girl","volume":"27","author":"Besbas","year":"2014","journal-title":"J Nephrol"},{"key":"10.1016\/j.transci.2016.04.012_bib0575","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.2215\/CJN.01360215","article-title":"Eculizumab in pediatric dense deposit disease","volume":"10","author":"Oosterveld","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.transci.2016.04.012_bib0580","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s00431-010-1279-3","article-title":"IgA nephropathy associated with a novel N-terminal mutation in factor H","volume":"170","author":"Schmitt","year":"2011","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.transci.2016.04.012_bib0585","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/j.molimm.2008.12.002","article-title":"Is complement factor H a susceptibility factor for IgA nephropathy","volume":"46","author":"Edey","year":"2009","journal-title":"Mol Immunol"},{"key":"10.1016\/j.transci.2016.04.012_bib0590","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1007\/s00467-014-2863-y","article-title":"Eculizumab treatment for rescue of renal function in IgA nephropathy","volume":"29","author":"Rosenblad","year":"2014","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.transci.2016.04.012_bib0595","first-page":"1","article-title":"Rare variants in the complement factor H-related protein 5 gene contribute to genetic susceptibility to IgA nephropathy","author":"Zhai","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.transci.2016.04.012_bib0600","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1093\/ckj\/sfv076","article-title":"Use of eculizumab in crescentic IgA nephropathy: proof of principle and conundrum","volume":"8","author":"Ring","year":"2015","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.transci.2016.04.012_bib0605","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s00467-014-2944-y","article-title":"Dramatic effects of eculizumab in a child with diffuse proliferative lupus nephritis resistant to conventional therapy","volume":"30","author":"Coppo","year":"2015","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.transci.2016.04.012_bib0610","first-page":"2286","article-title":"Eculizumab as rescue therapy in severe resistant lupus nephritis","volume":"54","author":"Pickering","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.transci.2016.04.012_bib0615","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1053\/j.ajkd.2014.07.031","article-title":"Thrombotic microangiopathy in systemic lupus erythematosus: efficacy of eculizumab","volume":"65","author":"El-Husseini","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.transci.2016.04.012_bib0620","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/ajt.12540","article-title":"Eculizumab prevents recurrent antiphospholipid antibody syndrome and enables successful renal transplantation","volume":"14","author":"Lonze","year":"2014","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transci.2016.04.012_bib0625","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1097\/MD.0000000000000143","article-title":"Efficacy of eculizumab in a patient with immunoadsorption-dependent catastrophic antiphospholipid syndrome: a case report","volume":"93","author":"Kronbichler","year":"2014","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.transci.2016.04.012_bib0630","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1002\/art.34440","article-title":"Brief report: induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab","volume":"64","author":"Shapira","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.transci.2016.04.012_bib0635","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/RHU.0000000000000290","article-title":"Eculizumab induces sustained remission in a patient with refractory primary catastrophic antiphospholipid syndrome","volume":"21","author":"Zikos","year":"2015","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.transci.2016.04.012_bib0640","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1111\/ajt.12319","article-title":"Eculizumab improves posttransplant thrombotic microangiopathy due to antiphospholipid syndrome recurrence but fails to prevent chronic vascular changes","volume":"13","author":"Canaud","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transci.2016.04.012_bib0645","first-page":"1554","article-title":"Coexistence of atypical HUS with MPGN and ANCA associated vasculitis","volume":"28","author":"Sathe","year":"2013","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.transci.2016.04.012_bib0650","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1097\/AOG.0b013e31828e2612","article-title":"Eculizumab for atypical hemolytic uremic syndrome in pregnancy","volume":"122","author":"Ardissino","year":"2013","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.transci.2016.04.012_bib0655","doi-asserted-by":"crossref","first-page":"76","DOI":"10.7326\/0003-4819-159-1-201307020-00023","article-title":"Successful treatment of the postpartum atypical hemolytic uremic syndrome with eculizumab","volume":"159","author":"Zschiedrich","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.transci.2016.04.012_bib0660","first-page":"i310","article-title":"Postpartum atypical hemolytic uremic syndrome in a young adult treated with eculizumab","volume":"28","author":"Kourouklaris","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.transci.2016.04.012_bib0665","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1053\/j.ajkd.2004.12.004","article-title":"Late-onset thrombocytic microangiopathy caused by cblC disease: association with a factor H mutation","volume":"45","author":"Guigonis","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.transci.2016.04.012_bib0670","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1053\/j.ajkd.2013.08.031","article-title":"Adult-onset eculizumab-resistant hemolytic uremic syndrome associated with cobalamin C deficiency","volume":"63","author":"Cornec-Le Gall","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.transci.2016.04.012_bib0675","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1093\/ckj\/sft078","article-title":"Eculizumab and drug-induced haemolytic-uraemic syndrome","volume":"6","author":"Faguer","year":"2013","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.transci.2016.04.012_bib0680","doi-asserted-by":"crossref","first-page":"B20","DOI":"10.1053\/j.ajkd.2013.02.022","article-title":"Doxorubicin induced thrombotic microangiopathy-2 case reports of this unknown association","volume":"61","author":"Ansari","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.transci.2016.04.012_bib0685","first-page":"E30","article-title":"Eculizumab therapy for gemcitabine induced hemolytic uremic syndrome: case series and concise review","volume":"5","author":"Al Ustwani","year":"2014","journal-title":"J Gastrointest Oncol"},{"key":"10.1016\/j.transci.2016.04.012_bib0690","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1681\/ASN.2013080886","article-title":"Phenotypic expansion of DGKE-associated diseases","volume":"25","author":"Westland","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.transci.2016.04.012_bib0695","first-page":"e1923","article-title":"Measuring the 50% haemolytic complement (CH50) activity of serum","volume":"37","author":"Costabile","year":"2010","journal-title":"J Vis Exp"},{"key":"10.1016\/j.transci.2016.04.012_bib0700","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/0022-1759(91)90130-8","article-title":"Simple quantitative haemolytic microassay for determination of complement alternative pathway activation (AP50)","volume":"140","author":"Servais","year":"1991","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.transci.2016.04.012_bib0705","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jim.2004.11.016","article-title":"Functional analysis of the classical, alternative, and MBL pathways of the complement system: standardization and validation of a simple ELISA","volume":"296","author":"Seelen","year":"2005","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.transci.2016.04.012_bib0710","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jim.2010.12.020","article-title":"Alternative complement pathway assessment in patients with atypical HUS","volume":"365","author":"Roumenina","year":"2011","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.transci.2016.04.012_bib0715","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.molimm.2004.01.003","article-title":"Functional analysis in serum from atypical Hemolytic Uremic Syndrome patients reveals impaired protection of host cells associated with mutations in factor H","volume":"41","author":"S\u00e1nchez-Corral","year":"2004","journal-title":"Mol Immunol"},{"key":"10.1016\/j.transci.2016.04.012_bib0720","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.molimm.2012.10.044","article-title":"Monitoring and modeling treatment of atypical hemolytic uremic syndrome","volume":"54","author":"Heinen","year":"2013","journal-title":"Mol Immunol"},{"key":"10.1016\/j.transci.2016.04.012_bib0725","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.clim.2015.05.018","article-title":"Sensitive, reliable and easy-performed laboratory monitoring of eculizumab therapy in atypical hemolytic uremic syndrome","volume":"160","author":"Volokhina","year":"2015","journal-title":"Clin Immunol"},{"key":"10.1016\/j.transci.2016.04.012_bib0730","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1111\/jth.12615","article-title":"Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome","volume":"12","author":"Cugno","year":"2014","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.transci.2016.04.012_bib0735","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1182\/blood-2014-03-560540","article-title":"Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab","volume":"125","author":"Peffault de Latour","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.transci.2016.04.012_bib0740","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1182\/blood-2014-02-558296","article-title":"Dynamics of complement activation in aHUS and how to monitor eculizumab therapy","volume":"124","author":"Noris","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.transci.2016.04.012_bib0745","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.blre.2014.11.001","article-title":"A new paradigm: diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury","volume":"29","author":"Jodele","year":"2015","journal-title":"Blood Rev"},{"key":"10.1016\/j.transci.2016.04.012_bib0750","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1055\/s-2006-939768","article-title":"Terminal complement complex (C5b-9) in children with recurrent hemolytic uremic syndrome","volume":"32","author":"Pr\u00fcfer","year":"2006","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.transci.2016.04.012_bib0755","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1182\/blood-2013-12-547067","article-title":"Biomarkers of terminal complement activation confirm the diagnosis of aHUS and differentiate aHUS from TTP","volume":"123","author":"Cataland","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.transci.2016.04.012_bib0760","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.1182\/blood-2014-09-600411","article-title":"Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS","volume":"125","author":"Cofiell","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.transci.2016.04.012_bib0765","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/qjmed\/hcv082","article-title":"A national specialized service in England for atypical haemolytic uraemic syndrome-the first year's experience","volume":"109","author":"Sheerin","year":"2016","journal-title":"QJM"},{"key":"10.1016\/j.transci.2016.04.012_bib0770","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1053\/j.ajkd.2015.04.010","article-title":"Discontinuation of eculizumab treatment in atypical hemolytic uremic syndrome: an update","volume":"66","author":"Ardissino","year":"2015","journal-title":"Am J Kidney Dis"}],"container-title":["Transfusion and Apheresis Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050216300143?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050216300143?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,16]],"date-time":"2024-06-16T04:11:26Z","timestamp":1718511086000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1473050216300143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":153,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["S1473050216300143"],"URL":"https:\/\/doi.org\/10.1016\/j.transci.2016.04.012","relation":{},"ISSN":["1473-0502"],"issn-type":[{"value":"1473-0502","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The alternative pathway of complement and the thrombotic microangiopathies","name":"articletitle","label":"Article Title"},{"value":"Transfusion and Apheresis Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transci.2016.04.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}